Company Bio

• Website
• LinkedIn

Asthma care often relies on symptoms and lung function tests, which do not directly measure airway inflammation,  the main driver of many asthma cases. This can result in delayed diagnosis, trial-and-error treatment, and poor disease control.

FeNO breath testing solves this by providing a fast, non-invasive, and objective measurement of airway inflammation through nitric oxide levels in exhaled breath. It helps identify patients with eosinophilic (Type 2) asthma who are likely to respond to inhaled corticosteroids.

By making inflammation visible, FeNO enables earlier diagnosis, personalized treatment, better monitoring of therapy effectiveness and adherence, and improved asthma control with fewer exacerbations.